Literature DB >> 32354910

Significance of Primary Malignant Tumors on the Outcome of Patients With Resected Gastrointestinal Stromal Tumors.

Shuzo Kohno1, Hiroaki Aoki2, Masaichi Ogawa2, Kazuhiko Yoshida2, Katsuhiko Yanaga3.   

Abstract

AIM: This study aimed to clarify the significance of primary malignant tumors for the outcome of resected gastrointestinal stromal tumors (GISTs). PATIENTS AND METHODS: The medical history, pathological findings and prognosis of 66 patients with GISTs resected at our institute between January 2003 and December 2018 were investigated retrospectively and compared statistically.
RESULTS: Among 66 patients with GISTs, 24 (36%) had concomitant malignant tumors. In an average study period of 57 months, one patient died from GIST, seven from other malignant tumors, and one from another disease. Only coexistence of GIST and other malignant tumors was recognized as a prognostic factor. Increasing age was significantly correlated with other malignant tumor in combination with GIST. When comparing patients with GIST alone and GIST with other malignant tumors, the latter showed significantly poorer prognosis.
CONCLUSION: Coexistence of other malignant tumors was commonly observed in patients with GIST, and was associated with poorer prognosis. This association should be carefully considered and monitored in patients with GISTs. Copyright
© 2020, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.

Entities:  

Keywords:  Gastrointestinal stromal tumor; prognostic factor; second cancer; second malignancy

Mesh:

Year:  2020        PMID: 32354910      PMCID: PMC7279818          DOI: 10.21873/invivo.11893

Source DB:  PubMed          Journal:  In Vivo        ISSN: 0258-851X            Impact factor:   2.155


  29 in total

1.  An audit of surgical management of gastrointestinal stromal tumours (GIST).

Authors:  P Bucher; J-F Egger; P Gervaz; F Ris; D Weintraub; P Villiger; L H Buhler; Ph Morel
Journal:  Eur J Surg Oncol       Date:  2006-01-18       Impact factor: 4.424

2.  Survival of patients with multiple primary malignancies: a study of 783 patients with gastrointestinal stromal tumor.

Authors:  R K Pandurengan; A G Dumont; D M Araujo; J A Ludwig; V Ravi; S Patel; J Garber; R S Benjamin; S S Strom; J C Trent
Journal:  Ann Oncol       Date:  2010-03-26       Impact factor: 32.976

3.  Synchronous gastrointestinal stromal tumors (GIST) and other primary cancers: case series of a single institution experience.

Authors:  Sheila S Ferreira; Gustavo Werutsky; Marcelo Garcia Toneto; Jarcedy Machado Alves; Christina Duarte Piantá; Raquel Cristine Breunig; Adriana Brondani da Rocha; Ivana Grivicich; Bernardo Garicochea
Journal:  Int J Surg       Date:  2010-04-07       Impact factor: 6.071

4.  Prevalence of Prior Cancer Among Persons Newly Diagnosed With Cancer: An Initial Report From the Surveillance, Epidemiology, and End Results Program.

Authors:  Caitlin C Murphy; David E Gerber; Sandi L Pruitt
Journal:  JAMA Oncol       Date:  2018-06-01       Impact factor: 31.777

Review 5.  Gastrointestinal stromal tumors--definition, clinical, histological, immunohistochemical, and molecular genetic features and differential diagnosis.

Authors:  M Miettinen; J Lasota
Journal:  Virchows Arch       Date:  2001-01       Impact factor: 4.064

Review 6.  Gastrointestinal stromal tumors: review on morphology, molecular pathology, prognosis, and differential diagnosis.

Authors:  Markku Miettinen; Jerzy Lasota
Journal:  Arch Pathol Lab Med       Date:  2006-10       Impact factor: 5.534

7.  Synchronous presentation of GISTs and other primary neoplasms: a single center experience.

Authors:  Niki Arnogiannaki; Ioanna Martzoukou; Panteleimon Kountourakis; Efthymios Dimitriadis; Antigoni Papathanasaki; Evangelos Nastoulis; Maria Gazalidou; Anna Fida; Nikiforos Apostolikas; Niki Joan Agnantis
Journal:  In Vivo       Date:  2010 Jan-Feb       Impact factor: 2.155

8.  Time to Definitive Failure to the First Tyrosine Kinase Inhibitor in Localized GI Stromal Tumors Treated With Imatinib As an Adjuvant: A European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Intergroup Randomized Trial in Collaboration With the Australasian Gastro-Intestinal Trials Group, UNICANCER, French Sarcoma Group, Italian Sarcoma Group, and Spanish Group for Research on Sarcomas.

Authors:  Paolo G Casali; Axel Le Cesne; Andres Poveda Velasco; Dusan Kotasek; Piotr Rutkowski; Peter Hohenberger; Elena Fumagalli; Ian R Judson; Antoine Italiano; Hans Gelderblom; Antoine Adenis; Jörg T Hartmann; Florence Duffaud; David Goldstein; Javier M Broto; Alessandro Gronchi; Angelo P Dei Tos; Sandrine Marréaud; Winette T A van der Graaf; John R Zalcberg; Saskia Litière; Jean-Yves Blay
Journal:  J Clin Oncol       Date:  2015-11-16       Impact factor: 44.544

9.  Therapeutic consequences from molecular biology for gastrointestinal stromal tumor patients affected by neurofibromatosis type 1.

Authors:  Chiara Mussi; Hans-Ulrich Schildhaus; Alessandro Gronchi; Eva Wardelmann; Peter Hohenberger
Journal:  Clin Cancer Res       Date:  2008-07-15       Impact factor: 12.531

10.  A nomogram to predict disease-free survival after surgical resection of GIST.

Authors:  Danielle A Bischof; Yuhree Kim; Ramy Behman; Paul J Karanicolas; Fayez A Quereshy; Dan G Blazer; Shishir K Maithel; T Clark Gamblin; Todd W Bauer; Timothy M Pawlik
Journal:  J Gastrointest Surg       Date:  2014-09-23       Impact factor: 3.452

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.